Why Is bioAffinity Technologies Stock Surging Tuesday?

Benzinga_recent_news03-17 22:32

bioAffinity Technologies Inc (NASDAQ:BIAF) shares are trading higher on Tuesday morning. The move follows the release of a new clinical case study. The study highlights the benefits of adding CyPath ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620755504?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/17/Cancer---Heart-Shape-To-Represent-Medica.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-03-17 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620755504","market":"sh","top_or_hot":-1,"title":"Why Is bioAffinity Technologies Stock Surging Tuesday?","media":"Benzinga_recent_news","content":"<div>\n<p>bioAffinity Technologies Inc (NASDAQ:BIAF) shares are trading higher on Tuesday morning.\nThe move follows the release of a new clinical case study. The study highlights the benefits of adding CyPath ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/03/51298914/why-is-bioaffinity-technologies-stock-surging-tuesday\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is bioAffinity Technologies Stock Surging Tuesday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is bioAffinity Technologies Stock Surging Tuesday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-17 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/03/51298914/why-is-bioaffinity-technologies-stock-surging-tuesday><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>bioAffinity Technologies Inc (NASDAQ:BIAF) shares are trading higher on Tuesday morning.\nThe move follows the release of a new clinical case study. The study highlights the benefits of adding CyPath ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/03/51298914/why-is-bioaffinity-technologies-stock-surging-tuesday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51298914/why-is-bioaffinity-technologies-stock-surging-tuesday","article_id":"2620755504","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/17/Cancer---Heart-Shape-To-Represent-Medica.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51298914/why-is-bioaffinity-technologies-stock-surging-tuesday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620755504","pubTimestamp":1773757920,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"bioAffinity Technologies (BIAF) stock surges Tuesday after a new case study confirms CyPath Lung's role in noninvasive cancer diagnostics. Details here.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BIAF":"bioAffinity Technologies, Inc."},"translate_title":"为什么bioAffinity Technologies股价周二飙升？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIAF":1},"content_text":"bioAffinity Technologies Inc (NASDAQ:BIAF) shares are trading higher on Tuesday morning.\nThe move follows the release of a new clinical case study. The study highlights the benefits of adding CyPath Lung to the diagnostic pathway.\nThe company released data regarding a 71-year-old former smoker with multiple pulmonary nodules. Traditionally, such cases lead to invasive biopsies. However, the CyPath Lung test returned a result of \"Unlikely Malignancy.\"\nA follow-up scan in October confirmed the nodules were benign.\n\"Multiple small nodules in a high-risk patient pose a diagnostic challenge,\" said Daya Nadarajah, MD, the patient's pulmonologist.\nHe noted the negative result provided comfort in waiting for a follow-up scan.\nGordon Downie, MD, PhD, Chief Medical Officer, stated the test reduces patient anxiety and lowers healthcare costs. It helps avoid \"expensive, invasive and often risky procedures when they are not necessary,\" according to Downie.\nThe surge follows a period of high volatility for the biotech firm. While the stock cooled on Monday, it saw a massive 120% rally last Friday. That gain was driven by strong growth in its flagship diagnostic tool.\nIn 2025, CyPath Lung revenue rose 87% year-over-year. The number of tests performed jumped 99%. Management is currently moving away from lower-margin lab services to focus on this high-growth flagship product.\nTraders are now shifting focus to the upcoming fourth-quarter earnings report on March 30. Analysts expect a loss per share of $2.70 on revenue of $1.41 million.\nThe company ended 2025 with $6.5 million in cash. This followed approximately $16.9 million in financings.\nBIAF Price Action: bioAffinity Technologies shares were up 41.37% at $2.70 at the time of publication on Tuesday, according to Benzinga Pro data.\nPhoto via Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620755504","isCrawlerRequest":true}